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The challenge of serodiagnosis of sleeping sickness in the 
context of elimination 
Gambiense human African trypanosomiasis (HAT), or 
sleeping sickness, is a neglected tropical disease that 
has been targeted for elimination as a public health 
problem by 2020.1 Although this goal is challenging, 
it now seems achievable. Control eﬀ orts, sustained 
mainly by mobile teams who screen populations at risk 
with the Card Agglutination Test for Trypanosomiasis 
(CATT) and treat patients if conﬁ rmed by microscopic 
parasitological tests, have led to a rapid decrease 
in disease prevalence. Incidence passed below the 
symbolic number of 10 000 newly reported cases 
in 2009 and reached 7216 in 2012.2 Furthermore, 
important innovations in terms of diagnosis and 
treatment are now in development, generating great 
hopes that sustainable control strategies could be 
implemented. Among these achievements is the 
forthcoming availability of lateral ﬂ ow rapid diagnostic 
tests that might be used for serodiagnosis of infection 
in place of CATT, which requires an electrical supply, 
a cold chain, and trained personnel. Alongside the 
elimination process, decreased disease prevalence 
means that screening by mobile teams will become 
less and less cost eﬀ ective. Thus, integration of HAT 
diagnosis into the endemic country health systems 
needs to be promoted. Rapid diagnostic tests that do 
not require any speciﬁ c equipment and are easy to use 
should help greatly in the development of an eﬀ ective 
passive surveillance system in primary health-care 
centres.
In The Lancet Global Health, Philippe Büscher and 
colleagues3 present the ﬁ rst formal assessment under 
ﬁ eld conditions of the HAT Sero-K-SeT rapid diagnostic 
test and compared its diagnostic accuracy with two 
other current serological tests: CATT and immune 
trypanolysis (a very sensitive and speciﬁ c test that 
requires laboratory conditions). The study was done 
in the Bandundu province of DR Congo during an 
active screening campaign. The investigators noted 
no signiﬁ cant diﬀ erence in sensitivity and speciﬁ city 
between the three tests and concluded that the accuracy 
of HAT Sero-K-SeT is adequate for HAT serodiagnosis, 
and thus that the test could be implemented for passive 
surveillance at peripheral health facilities. 
Notably, another rapid diagnostic test developed by 
the Foundation for Innovative Diagnostics (FIND) in 
collaboration with SD Bioline4 has also been developed. 
The two tests are based on the antibody recognition of the 
same trypanosome variant surface glycoproteins (LiTat 
1.3 and LiTat 1.5). Additional eﬀ orts are now needed 
to assess their accuracy and implementation as passive 
surveillance techniques in diﬀ erent areas in central and 
west Africa because the variable antigen type recognition 
pattern of Trypanosoma brucei (T b) gambiense is known 
to diﬀ er geographically5–7 and because integration of 
HAT diagnosis in the primary health-care system is 
challenging.8 
Nevertheless, availability of such rapid serodiagnostic 
tests only partly simpliﬁ es the diagnosis of HAT. As for 
CATT, these rapid diagnostic tests are only serological 
suspicion tests and parasitological conﬁ rmation 
by central laboratories is needed before treatment 
can be started. This issue arises because all available 
serological tests are hindered by insuﬃ  cient speciﬁ city, 
and fears surround overtreatment with present drugs 
that are toxic, complex to administer, and require 
long-term admission to speciﬁ c treatment centres. 
In this regard, new oral drugs such as fexinidazole2,9 
have now entered phase 2 clinical trials and might 
soon become available. Second-generation rapid 
diagnostic tests, based on other recombinant proteins 
or peptides, are also under development as continuous 
eﬀ orts to improve HAT diagnosis. These eﬀ orts 
should be encouraged because they might (alone or 
in combination) signiﬁ cantly increase the speciﬁ city 
of serological diagnosis and thus simplify treatment 
decisions. The possibility of being able to treat patients 
with an oral drug on the basis of a rapid diagnostic test 
or combination of rapid diagnostic tests would be a 
giant leap towards the elimination of sleeping sickness: 
a dream that is now in sight.
A healthy competition exists between several 
groups to develop HAT rapid diagnostic tests, which 
should improve quality and provide options in case 
one test fails to improve diagnostic accuracy. As a 
neglected tropical disease and with decreasing disease 
prevalence, progressive commercial disinterest is a 
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possibility for HAT. Thus, reliance on a single rapid 
diagnostic test for which production could be stopped 
for economic reasons is dangerous, and could harm 
the elimination strategy. All the political, ﬁ nancial, and 
technical ingredients seem to be in place to make HAT 
elimination a success story.10 We should not miss this 
historical opportunity.
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